Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data
As new therapies emerge, this study highlights the comparative effectiveness of BTKis in the real world, potentially informing current clinical practice.
Authors
- Sabyasachi Ghosh (ORCID: https://orcid.org/0000-0003-1212-824X)
- Erin Cook (ORCID: https://orcid.org/0000-0001-9737-9130)
- Lindsey A. Fitzgerald (ORCID: https://orcid.org/0000-0001-5988-2878)
- Wasiulla Khan
- Lizheng Shi (ORCID: https://orcid.org/0000-0002-7827-6766)
- Solomon A. Graf (ORCID: https://orcid.org/0000-0002-9475-3016)
- Fan Mu (ORCID: https://orcid.org/0000-0003-0252-0387)
- Yilu Lin (ORCID: https://orcid.org/0000-0001-7040-4287)
- Angela Lax (ORCID: https://orcid.org/0000-0001-9577-8904)
- Eric Q. Wu (ORCID: https://orcid.org/0000-0001-8379-3373)
- Alex Bokun (ORCID: https://orcid.org/0000-0002-2622-6513)
- Jingyi Chen (ORCID: https://orcid.org/0009-0007-0141-2241)
- Grace Chen (ORCID: https://orcid.org/0009-0002-5979-3853)
- Zaina Parvez Qureshi (ORCID: https://orcid.org/0000-0003-3231-0049)
Institutions
- Tulane University (US)
- Johnson & Johnson (United States) (US)
- University of Washington (US)
- Huntsman Cancer Institute (US)
- Fred Hutch Cancer Center (US)
- VA Puget Sound Health Care System (US)
- Southeast Louisiana Veterans Health Care System (US)
- George E. Wahlen Department of VA Medical Center (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-12-03
- DOI
- https://doi.org/10.18553/jmcp.2025.25169
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00